Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2022

View Archived Issues

Preprints age well, manuscript preprint shows

New DNA intercalator/topo II inhibitor shows improved anticancer activity over doxorubicin

Prodrug form target of JBP-485 and vitamin E developed to treat NASH

GMQ-3 shows promising efficacy in models of lung cancer

Discovery of novel BU-4664L derivatives with potential anticancer activity

Medshine Discovery patents new GLP-1 receptor agonists

Chinese researchers disclose SOS1 inhibitors

Betta Pharmaceuticals divulges new PTPN11 inhibitors

Roche presents compounds for Gram-negative bacterial infections

Mission Therapeutics synthesizes USP30 inhibitors

Novel halogenated phenoxychalcones described with activity in breast cancer cell lines

Siglec-15 promotes osteosarcoma tumor progression

Inhaled remdesivir shows efficacy in nonhuman primate model of SARS-CoV-2 infection

VC-2 vaccine confers protection against viral ocular immunopathogenesis through T-cell infiltration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...